1	Systematic surveillance of SARS-CoV-2 reveals dynamics of variant mutagenesis
2	and transmission in a large urban population
3	
4	Marie-Ming Aynaud ^{1,8} , Lauren Caldwell ^{1,8} , Khalid N. Al-Zahrani ^{1,8} , Seda Barutcu ¹ , Kin
5	Chan ^{1,7} , Andreea Obersterescu ¹ , Abiodun A. Ogunjimi ¹ , Min Jin ² , Kathleen-Rose
6	Zakoor ¹ , Shyam Patel ^{1,3} , Ron Padilla ¹ , Mark Jen ^{1,7} , Princess Mae Veniegas ⁴ , Nursrin
7	Dewsi ⁴ , Filiam Yonathan ⁴ , Lucy Zhang ⁴ , Amelia Ayson-Fortunato ⁴ , Analiza Aquino ⁴ , Paul
8	Krzyzanowski ⁵ , Jared Simpson ⁵ , John Bartlett ⁵ , Ilinca Lungu ⁵ , Bradly G. Wouters ⁶ , James
9	M. Rini ² , Michael Gekas ⁴ , Susan Poutanen ⁴ , Laurence Pelletier ^{1,3} , Tony Mazzulli ^{4,7} , and
10	Jeffrey L. Wrana ^{1,3,7*}
11	
12	Authors affiliation
13	¹ Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, M5G
14	1X5, Canada.
15	² Departments of Molecular Genetics and Biochemistry, University of Toronto, MaRS
16	Center, Toronto, Ontario, M5G 1M1, Canada
17	³ Department of Molecular Genetics, Donnelly Centre, University of Toronto, Toronto,
18	Ontario, M5S 3E1, Canada.
19	⁴ Department of Microbiology, Mount Sinai Hospital/University Health Network, Toronto,
20	Ontario, M5G 1X5, Canada.
21	⁵ Ontario Institute for Cancer Research, Toronto General Hospital, Toronto, ON M5G 0A3
22	⁶ Princess Margaret Cancer Centre and Campbell Family Institute for Cancer Research,
23	University Health Network, Toronto, Ontario, M5G 2C4, Canada

- 24 ⁷The Network Biology Collaborative Centre (NBCC), Mount Sinai Hospital, Toronto,
- 25 Ontario, M5G 1X5, Canada.
- 26 ⁸These authors contributed equally
- 27 *Corresponding author: Dr. Jeffrey L. Wrana, wrana@lunenfeld.ca
- 28

30 Abstract

31 Highly mutable pathogens generate viral diversity that impacts virulence, transmissibility, 32 treatment, and thwarts acquired immunity. We previously described C19-SPAR-Seq, a 33 high-throughput, next-generation sequencing platform to detect SARS-CoV-2 that we 34 deployed to systematically profile variant dynamics of SARS-CoV-2 for over 3 years in a 35 large, North American urban environment (Toronto, Canada). Sequencing of the ACE2 36 receptor binding motif and polybasic furin cleavage site of Spike in over 70,000 patients 37 revealed that population sweeps of canonical variants of concern (VOCs) occurred in 38 repeating wavelets. Furthermore, we found that subvariants and putative quasi-species 39 with alterations characteristic of future VOCs and/or predicted to be functionally important 40 arose frequently, but always extinguished. Systematic screening of functionally relevant 41 domains in pathogens could thus provide a powerful tool for monitoring spread and 42 mutational trajectories, particularly those with zoonotic potential.

44 Introduction

Repeated outbreaks of respiratory viral infections over the past 20 years culminated in the COVID-19 pandemic caused by SARS-CoV-2¹, with more than 700 million cases and over 7 million deaths confirmed worldwide². SARS-CoV-2 thus presented unique challenges for public health agencies trying to manage both travel and local spread. In particular, long incubation and recovery times coupled with large numbers of asymptomatic/mildly symptomatic patients that unknowingly communicate disease drove the pandemic to unprecedented levels.

52

53 The RNA SARS-CoV-2 virus is a member of the coronavirus family characterized by high 54 mutational rates that lead to genetic diversity. The main variants impacting 55 transmissibility, severity, and/or immunity are classified as Variants of Concern (VOCs). The first VOC, Alpha (B.1.1.7) was identified in September 2020 in the United Kingdom^{3,} 56 ⁴, followed by the identification of other VOCs that arose in a variety of regions including 57 58 Beta (B.1.351) in South Africa in May 2020⁵, Gamma (P.1) in Brazil in November 2020⁶, Delta (B.1.617.2) in India in October 2020², and Omicron (B.1.1.529) arising in various 59 60 countries in November 2021². The continuous process of genetic variation, competition, 61 and selection results in the detection of major and minor subvariants within these VOCs⁷. 62 ⁸. The equilibrium-like status of a given VOC collapses when an advantageous new 63 mutant emerges and outcompetes the pre-existing VOC within the population.

64

As the scale of SARS-CoV-2 transmission spiralled, the capacity of whole genome
approaches to systematically map genetic alterations at a population scale was quickly

medRxiv preprint doi: https://doi.org/10.1101/2024.07.25.24311007; this version posted July 29, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

67 overwhelmed, financially unsustainable, and slow, making it difficult to track emerging 68 new variants until they had already escaped into broader regional and then global 69 populations. We previously developed C19-SPAR-Seq (COVID-19 screening using 70 Systematic Parallel Analysis of RNA coupled to Sequencing)⁹ as a high throughput next-71 generation sequencing (NGS)-based strategy to enable rapid detection of SARS-CoV-2. 72 Therefore, as variants began emerging in the Fall of 2020, we pivoted the application of 73 C19-SPAR-Seq to mapping the evolutionary dynamics of two key functional regions of 74 SARS-CoV-2 in a large North American urban center. Here, we describe optimization and 75 automation of the C19-SPAR-Seq pipeline and describe its use in providing near real-76 time profiling of 73,510 SARS-CoV-2-positive patients collected within the Greater 77 Toronto Area (GTA; ~6M people) from December 2020 to March 2023. This screening 78 effort identified the early emergence of VOCs and revealed repeated acceleration and 79 deceleration phases of VOC transmission that were unrelated to non-pharmaceutical 80 interventions (NPIs). Furthermore, we show that subvariants frequently arise within VOC 81 populations, but never spread, and that by tracking subvariants and minor putative viral 82 guasispecies, alterations that foreshadowed future evolutionary SARS-CoV-2 trajectories 83 could be revealed. Systematic profiling of functional domains in highly mutable viruses 84 could thus provide an important tool to prevent and manage future pandemics.

- 85
- 86
- 87
- 88
- 89

90 Results

91 Integration of C19-SPAR-Seq into a Clinical Pipeline.

92 We previously established a C19-SPAR-Seq platform for high throughput detection of 93 SARS-CoV-2⁹ in which amplicons were designed over the RNA-dependent RNA 94 polymerase (*RdRP*), and two key functional regions of the Spike (S) gene: the receptor-95 binding motif (S-Rbm) and the furin cleavage site (S-Pbs, FCS). In light of the global 96 emergence of SARS-CoV-2 VOCs in the fall of 2020^{5, 6, 10}, we set out to link C19-SPAR-97 Seq into a clinical diagnostics pipeline (Clinical Diagnostics Lab, Department of 98 Microbiology at Mount Sinai Hospital and University Health Network) that provided COVID19 diagnostics services to the Greater Toronto Area (GTA) (Fig. 1a, 99 100 Supplementary Fig. 1, Supplementary Table 1). Starting in December 2020 we profiled 101 1,218 SARS-CoV-2 positive samples collected between December 17, 2020, and 102 January 28, 2021, then subsampled an average of 111 positive samples per week 103 between January 28, 2021 and May 19, 2021, prior to transitioning to testing all positive 104 samples in June 2021 (Fig. 1a; Supplementary Fig. 1). Importantly, we did not pre-select 105 samples based on C_T values from the initial qRT-PCR tests, but established several 106 guality control cutoffs: 1) total read counts for each amplicon within a given sample were 107 required to be greater than that of the negative control within each plate; 2) read counts 108 for S-Rbm had to be greater than two times the absolute deviation above the median 109 counts for S-Rbm within each plate; and 3) samples with low viral-reads were filtered out 110 if a sample's total viral counts were lower than the total viral counts of the negative control 111 within each plate. Of the initial 1,218 samples, only 20 failed to pass our quality control 112 filters, representing less than 2% of the samples (**Supplementary Table 2**). Importantly,

113 the remaining 98% of samples showed a high proportion of reads for all four amplicons 114 (Fig. 1b). To call variants in C19-SPAR-Seq data, we analyzed the top read count for 115 each amplicon following deep sequencing, and first focused on the major VOCs 116 highlighted by the WHO¹¹ that circulated in the global population in early 2021. This 117 showed that most of the samples had S-Rbm and S-Pbs sequences from the original 118 Wuhan strain (hereafter referred to as "wild type", WT). However, we also identified the 119 first cases of the WHO-designated variants of concern (VOCs), Alpha and Beta, detected 120 in the GTA (Fig. 1c,d) which we confirmed by whole genome sequencing (WGS) 121 (Supplementary Table 3). Together, this pilot analysis of the first 1,218 patients validated the C19-SPAR-Seq pipeline as an effective, scalable tool to accurately identify mutations 122 123 within two key functional domains of SARS-CoV-2-positive patient samples. Of note, 124 almost all VOCs that emerged between 2020 and 2023 were distinguishable based on 125 sequence variations in the S-Rbm and S-Pbs regions targeted by C19-SPAR-Seq version 126 1 (V1, Supplementary Fig. 1b).

127

128 Optimization of an improved C19-SPAR-Seq V2 pipeline

Having benchmarked the C19-SPAR-Seq V1 pipeline, and to facilitate its integration into a clinical diagnostics platform, we next developed a semi-automated pipeline for the rapid, systematic screening of SARS-CoV-2 variants (**Supplementary Fig. 2**) that included semi-automated library generation, sequence processing, and variant assignment. Briefly, PCR-positive samples were arrayed in 384-well formatted plates, processed, sequenced, analyzed, and a report generated with the pipeline providing the capacity for variant profiling within 24h (**Supplementary Fig. 2**). This pipeline was applied to profile

136 an average of 111 cases per week in early 2021 and was accelerated on June 1, 2021 to include all positive samples and daily screening by the summer of 2021, as increasing 137 138 numbers of VOCs were being detected globally, and the more aggressive Delta variant 139 had emerged (Fig. 1e). During the course of variant monitoring from December 17, 2020, 140 to March 27, 2023, a total of 2,786,028 PCR tests were performed of which 133,089 141 (4.88%) were SARS-CoV-2-positive, and less than 0.05% of tests were indeterminate 142 (Fig. 1f). Over the course of our analysis, we ran 73,510 of the 137,193 SARS-CoV-2-143 positive samples through the C19-SPAR-Seg platform; this represents 53.58% of all 144 positive cases, with 81.48% profiled after June 1, 2021 (Fig. 1f). Importantly, we found 145 that only 7,345 samples failed QC assessment despite not filtering for viral load (ie-Ct 146 values). This represented a failure rate of ~10% over the test period, showing that C19-147 SPAR-Seq can provide robust coverage of variants in a clinical diagnostic setting 148 (Supplementary Table 2).

149

150 Over the course of screening we also tracked the analytical performance of our pipeline 151 on a run-to-run basis and adjusted parameters to improve our standard operating 152 procedures as necessary (see Methods). For example, while the S-Rbm and S-Pbs 153 regions produced fingerprints that covered most VOCs, including most Omicron family 154 members (see below), this was not the case for Delta. Although Delta harbours a P681R 155 alteration in the S-Pbs that was captured, the S-Rbm region originally screened was WT, 156 and the characteristic T478K mutation in the S-Rbm was not covered (Supplementary Fig. 1b). When Delta emerged as a global threat, we rationalized that our pipeline was 157 158 amenable to changes in primer sequences that would capture new regions of interest,

159 and designed a new primer pair (S-Rbm V2 and pipeline version V2) which yields a larger 160 amplicon (Supplementary Fig. 3a) that covers an additional five amino acids (including T478) that contribute to ACE2 receptor binding^{12, 13}. We validated that the S-Rbm V2 161 162 primer pair performed well in our C19-SPAR-Seq assay by qRT-PCR (Supplementary 163 Fig. 3a) and multiplexed amplicon distribution by fragment analyzer (Supplementary Fig. 164 **3b**; right panel). One limitation of the V1 primer mixture was the high level of non-specific 165 amplification that was observed in the multiplex primer reaction (Supplementary Fig. 3b; 166 left panel), which required a size selection purification step using the Pippin Prep System 167 to purify the 220-350 bp fragment window prior to sequencing. However, the V2 primer 168 mixture that increased the S-Rbm amplicon by 35 bp, provided more specific amplification 169 products from the multiplex reaction (Supplementary Fig. 3b; right panel), obviating the 170 need for a size selection step. Systematic mapping of primer combinations could thus 171 improve technical performance in future iterations of C19-SPAR-Seq. Next, we validated 172 V2 against V1 in a diagnostic setting in four clinical runs, which contained a total of 94 173 samples. Comparison of both V1 and V2 in our C19-SPAR-Seq pipeline showed good 174 correlation of S-Rbm reads (Spearman Correlation of 0.82, r²=0.67; Supplementary Fig. 175 **3c**) without affecting the efficiency of the other primer sets (**Supplementary Fig. 4**). Most 176 importantly, mutation and variant calling was the same for each of the samples, but with 177 the added benefit that V2 provided direct sequence information around the T478K 178 mutation found in Delta (**Supplementary Data 2**).

179

Another potentially confounding factor in large-scale sequencing experiments is the risk
of sample mixing and/or crosswell contamination during the experimental setup and

182 workflow. To directly measure cross-well contamination rates in the PCR step we 183 developed S-Rbm V2 primer pairs that incorporated well-specific molecular identifiers 184 (barcodes; BC-S-Rbm V2) (Supplementary Fig. 5a, Supplementary Table 4). The 384 185 BC-S-Rbm V2 primer pairs were validated by qPCR on a control sample (data not shown) 186 and were employed to re-analyze 6 clinical runs (1,987 positive samples) across the 187 testing window that contained a representative mixture of WT, Alpha, Delta, and Omicron 188 B.1.1.529 VOCs. Of note, BC-S-Rbm V2 primers did not negatively affect library quality 189 (Supplementary Fig. 5b). We then measured contamination in each well as the 190 percentage of reads that do not contain the correct barcode pair. Across all these 191 barcoded clinical runs, we observed that 97% of all reads belonged to the correct well-192 barcode pair (Supplementary Fig. 5c, Supplementary Data 1). Importantly, samples 193 which contain a low percentage of correct well-barcode pairs all contained extremely low 194 total read counts, indicative of a failed PCR reaction. Therefore, these samples would 195 later be filtered out for having poor quality in the analysis pipeline (Supplementary Fig 196 6). In addition, we measured how often paired well-barcodes within a plate were found in 197 the incorrect well. This revealed that on average 2.5% of the total reads for any given 198 sample could be attributed to cross-well contamination (Supplementary Fig. 5d). 199 Importantly, mapping the spread of well-barcode mixing events revealed a stochastic 200 pattern of contamination across six independent clinical runs, indicating that there is not 201 a systematic error within our robotics pipeline and sample handling (Supplementary Fig. 202 7). Together, these studies show that the C19-SPAR-Seq pipeline is highly sensitive, 203 accurate, robust and adaptable to rapid modifications in the primer multiplexing step,

204 which is extremely advantageous when characterizing highly infectious and mutable 205 viruses such as C19-SARS-CoV-2.

206

207 **Population-level surveillance of variant dynamics by C19-SPAR-Seq.**

208 To track variant spread, we next integrated sequence information into a single dataset 209 (See methods). Each major VOC was detected within our jurisdiction, albeit with different 210 latencies from the first emergence worldwide (**Supplementary Table 5**). Of the VOCs 211 identified in the GTA, only Alpha, Delta, and four Omicron sublineages generated 212 dominant waves (Fig. 2, upper panel). Of the dominant VOCs, we noted that only a 213 single variant was dominant at any time, as noted in other jurisdictions (Fig. 2, lower 214 **panel**)^{14, 15}. We next assessed the transition between variants by calculating the cross-215 over point when each subsequent dominant VOC became proportionally more of the 216 tracked cases than the previous dominant VOC (Fig. 2, lower panel).

217

218 This showed a shift from WT to Alpha in late February 2021, from Alpha to Delta in June 219 2021, and Delta to Omicron B.1.1.529 in December 2021. As expected, Omicron 220 numbers and frequency dominated the population of variants by late December 2021, 221 with subsequent Omicron subvariants emerging with their first reported cases on 222 December 23, 2021 (BA.2/3), May 6, 2022 (BA.4/5), November 16, 2022 (XBB), and 223 December 8, 2022 (XBB.1.5) (Fig. 2, upper panel, Supplementary Table 5). In contrast 224 to these major VOCs, the Beta and Gamma variants displayed low steady-state infectivity 225 of <10% in the Spring of 2021, before extinguishing on August 7, 2021, and we grouped 226 them together for our analyses (Fig. 2). Furthermore, Mu (B.1.621.1), which arose in

Columbia in January 2021 was only detected in 89 samples, peaking in August 2021,
while Eta (B.1.525) which arose in the United Kingdom and Nigeria in December 2020
was only detected in 3 samples (Fig. 2, upper panel). Given their low frequency these
latter two were not further characterized in this study.

231

232 We postulated that the unique sequences of variants, combined with systematic, high 233 frequency screening, would provide a sensitive method to track the dynamics of SARS-234 CoV-2 spread within the population. To examine this, we first focused on Alpha, the first 235 major VOC that circulated in the GTA and tracked its emergence and expansion based 236 on the proportion of daily cases from February 6, 2021 (Day 1), until Alpha became the 237 dominant species (>50%; Day 32; March 10, 2021; Fig. 3a). We next fit linear models 238 along a sliding 5-day window (Fig. 3a, top panel, red lines) to quantify the expansion 239 rate (Fig. 3a, bottom panel, see methods for details). This showed expansion rates were 240 low in the beginning indicating a lag-phase in variant expansion. Interestingly, we 241 observed that Alpha did not expand at a homogeneous rate within the population, but 242 displayed distinct waves of accelerating and decelerating transmission (Fig. 3a, lower 243 panel). Analysis of the emergence of Delta (Fig. 3b) similarly showed highly dynamic 244 behaviour and acceleration/deceleration waves analogous to Alpha dynamics (Fig. 3b, 245 **lower panel**). This was followed by the emergence of Omicron, which displayed a lag 246 and then two phases of rapid acceleration (**Fig. 3c**). These data show that viral spread is 247 comprised of multiple, repeated wavelets of transmission.

248

249 The distinct patterns of viral spread prompted us to explore whether acceleration waves 250 were linked to NPIs. We therefore assessed major NPI policies implemented in the GTA 251 in 2021, in particular, stay-at-home orders and school openings and closings 252 (Supplementary Table 6). We overlaid NPI dates on our rate of change data for WT and 253 the three major VOCs (Fig. 3d) and found that changes in NPI policies were not 254 associated with alterations in the patterns of viral expansion. For example, between a 255 closing NPI (#4; return to stay-at-home order) and an opening NPI (#5; stay-at-home 256 order lifted), we noted 2 acceleration waves of Alpha, while the opening NPI (#5) was 257 followed by a mixed period of reduced rates of transmission. Similarly, Delta cases were initially dynamic until July 2021, but transitioned to a steady-state rate of transmission 258 259 despite societal-wide reopening that included the lifting of restrictions on gatherings (#13 260 to #14, August to September 2021; Fig 3d, Supplementary Table 6). Finally, the rapid 261 onset of Omicron, as initially observed (Fig. 2 upper panel) showed an extreme 262 acceleration and attempts to dampen Omicron spread by restricting travel (#15, Fig. 3d) 263 were followed by a rapid acceleration phase. Indeed, systematic, rapid C19-SPAR-Seq 264 screening showed substantive numbers of Omicron were already present in the GTA. 265 These analyses indicate that patterns of viral spread are not strongly affected by NPIs 266 and further suggest how near real-time monitoring of viral species can provide an 267 important tool to inform decisions around the introduction of public health measure 268 policies.

269

In December 2021, changes in provincial government policy that took effect on December
31, 2021 (#17, Fig. 3d), limited testing to high risk groups such as patients and staff in

272 health care settings, or people living in or working in First Nation, Inuit, and Métis 273 communities¹⁶, and significantly reduced population testing. Thus, subsequent 274 frequencies may not reflect alterations in the general GTA population. This reduction in 275 testing accessibility also had an immediate impact on our data collection. The total 276 samples collected and sequenced between December 25 and December 31, 2021 was 277 6,813, while in the week immediately after testing restrictions (January 1 to January 7, 278 2022), only 1,035 samples were collected and processed, marking an 84% drop in 279 samples. Due to the reduction in population-level data collection, we did not assess the 280 impact of NPIs implemented after December 2021.

281

282 Subvariants arise frequently in VOC populations

283 In the course of profiling known variant fingerprints, we noted that subvariants often arose 284 with additional changes to the S-Rbm and/or S-Pbs sequences. For example, our 285 preliminary screen of the first 1,219 samples revealed 3 VOCs with WT comprising 1,142 286 of the samples, Alpha (B.1.1.7) comprising 6, and Beta (B.1.351) comprising 1. Within 287 this group we noted 46 WT samples that possessed 12 distinct patterns of alterations in 288 the S-Rbm and S-Pbs (Fig. 4a). Three were mutations in S-Rbm (E484K, Y489Y, and 289 S494P), eight had mutations in the S-Pbs (N679K, P681H, P681H/S691S, P681R, 290 R682R, A684V, S691S, and I692I), and one had mutations in both regions 291 (E484K/Q677H) (Fig. 4a). In contrast, analysis of the RdRP region that is also 292 incorporated into the C19-SPAR-Seq amplicon set revealed 3 samples each with a 293 unique variant sequence (Fig. 4a). To validate the C19-SPAR-Seq results in the pilot 294 cohort. we confirmed the presence of these mutations by WGS (Supplementary Table

3), which showed these early variants all comprised the B strain and further showed that
samples harbouring N679K alterations were closely related (Fig. 4b), suggesting they
represent a small transmission cluster. In contrast, the other variants were more distant
and may represent sporadic introductions and/or *de novo* emergence of alterations.

299

300 We next expanded our analysis and annotated the S-Rbm and S-Pbs of all SARS-CoV-301 2 isolates profiled in the GTA from January 2021-March 2023 (66,165 QC-passing 302 samples). The WT and canonical VOCs accounted for 96.09% of all samples, with the 303 remaining 3.91% of samples containing additional changes in the S-Rbm and/or S-Pbs 304 (Supplementary Fig. 8, 9, Supplementary Data 3). In total we identified 393 non-305 canonical, unique alterations in VOCs, the vast majority of which (389 out of the 393 306 identified) were point mutations that changed the amino acid sequence (Figure 4c, 307 Supplementary Fig. 8, Supplementary Fig. 9d, Supplementary Data 3), while the 308 remaining 4 subvariants were an insertion and deletion in the S-Pbs (Supplementary 309 Fig. 10a) and 2 silent mutations in BA.4/5 and BA.2.75.2 respectively. To identify these 310 viral species and their dynamics within the population we next plotted each unique 311 sequence throughout the time course (Fig. 4c) and referred to these as VOC subvariants 312 (Fig. 4c, Supplementary Fig. 8, Supplementary Data 3). To assess if these mutational 313 calls reflected poor-quality samples, we quantified the top read count percentages, which 314 showed similar abundance for both canonical VOC and VOC subvariants across the 315 entire dataset (Supplementary Fig. 10b). We also analyzed *RdRP* and only found 38 316 nucleotide variants, which formed 34 unique amino acid variants distributed in 194 samples (0.29%; Supplementary Data 3). This indicates that, unlike the RdRP, the S-317

318 *Rbm* and *S-Pbs* regions are subject to much greater mutational dynamics 319 (Supplementary Fig. 9d), an observation consistent with evolutionary pressure 320 converging on these key functional regions for SARS-CoV-2 transmission and virulence, 321 and the fact that they are also primary targets of the immune system. In contrast to point 322 mutants, we only identified five unique stop-gain mutations, which would be predicted to 323 be disadvantageous for viral expansion (**Supplementary Data 3**). Similarly, while point 324 mutations in the S-Pbs were frequently observed, we identified only 1 example of an 325 insertion (seen in three samples), and one example of a deletion seen in two samples 326 (Supplementary Fig. 10a). Thus, deletions and insertions within the S-Rbm and S-Pbs 327 are extremely rare (Supplementary Data 3).

328

329 The dynamics of canonical VOCs within our data set shares the same patterns as those 330 worldwide, where each subsequent VOC outcompetes the previous one (Fig. 2). 331 However, we were curious as to how VOC subvariants behaved over time within the 332 population. To determine this, we aggregated all subvariants for each unique VOC and 333 plotted their frequencies within the population over time with respect to the canonical 334 VOC. Interestingly, VOC subvariant frequencies peaked weeks after the peak of the 335 canonical parental counterpart (Fig. 4d), suggesting that these subvariants arose within 336 the population after the introduction of the canonical version. Interestingly, Delta and 337 Omicron, which were two of the most dominant VOCs worldwide, had subvariants that 338 formed secondary waves that peaked while the canonical variant was declining (Fig. 4d). 339

340 We next sought to map how specific mutations and/or residues within the S-Rbm or S-341 Pbs were being selected for, or recurrently altered over time. To investigate this, we 342 calculated the frequency of mutations at each residue within the S-Rbm and S-Pbs 343 amplicons for each VOC (Fig. 5a). One of the most striking observations was the high 344 level of mutagenicity of the WT strain at positions E484, N501, N679, and P681, which 345 together accounted for 79.3% of the WT VOC subvariants (Fig. 5b, Supplementary Fig. 346 **9b,c)**. All of these residues were targeted for mutation in future VOCs, suggesting the WT 347 virus was frequently generating variants in these functionally important residues. 348 Furthermore, analysis of subvariant frequency showed that all VOCs frequently produced 349 mutants, except the Beta/Gamma and XBB VOCs which displayed low levels of 350 subvariant production (Supplementary Fig. 9a,b). Interestingly, Delta, which generated 351 the most subvariants (Supplementary Fig. 9b), showed a high enrichment for mutations 352 in the Omicron hotspots Q477, N501, and N679 (Fig. 5a and Supplementary Data 3). 353 Omicron BA.2.75 also showed high production of subvariants (**Supplementary Fig. 9c**); 354 the Omicron sublineage BA.4/5 often targeted Y473, Y489, A672, R683, and S691, most 355 of which were readily seen in previous VOC subvariants, and may represent avenues for 356 further evolution of SARS-CoV-2 (Fig. 5b). In contrast to S-Pbs and S-Rbm, we detected 357 very few subvariants in *RdRP* (**Supplementary Fig. 9d**).

358

To examine subvariant transmission within the population, we assessed the circulation time of the top 14 subvariants, which included both functional and non-functional mutations (**Figure 5b, left panel**). The median circulation time of subvariants with putative functional mutations (E484, P681, N501, F490) was 56 days compared to the

363 non-functional group (A684, S691, R682, A688, A672) that displayed a median time of 364 29 days. This indicates that functional subvariants tend to circulate longer than their non-365 functional counterparts (Figure 5b, right panel). These observations suggest that 366 alterations in specific residues recurrently arise *de novo* in the viral population, but without 367 selection pressure, subsequently subside. To directly test this, we compared the affinity 368 of ACE2 for S-RBMs corresponding to major VOCs, and a prominent Alpha subvariant 369 we identified, Alpha + F490L. All of the VOCs except for Delta showed a higher affinity to 370 ACE2 that reflected a slower off-rate for ACE2 binding *in vitro* (Supplementary Fig. 11). 371 Furthermore, Alpha+F490L displayed similar binding kinetics as canonical Alpha, 372 consistent with this variant S-Rbm not possessing a selective advantage. Rapidly 373 identifying novel subvariants and assessing their functional impact can thus provide a useful tool to predict the dynamics of spread through the population. Collectively, these 374 375 studies show that population-level surveillance of mutable viral pathogens, such as 376 SARS-CoV-2 provides an extremely useful tool in predicting hotspot and key residues 377 that will arise as major species in future lineages. Applying this strategy could thus provide 378 important predictive value in monitoring viral pathogens with potential cross-over 379 capability.

380

381 Detection of putative SARS-CoV-2 quasispecies by C19-SPAR-Seq

The concept of quasispecies reflects a model of evolution in which imperfect replication leads to the production of mutant clouds that in aggregate define the evolutionary unit of selection¹⁷. In the context of viral evolution, a quasispecies represents a large collection of mutant genomes, with the dominant sequence reflecting the variant with the highest

386 fitness within the cloud. As such, changes in selection pressure can alter which 387 quasispecies dominate the population. C19-SPAR-Seq provides deep profiling of SARS-388 CoV-2 sequences over functionally important regions of the S gene and we assigned 389 variants based on the major sequence (top read in the deep sequencing pipeline) 390 obtained from each sample. These top reads accounted for approximately 75% of all 391 mapped reads per sample on average across the entire dataset (Supplementary Fig. 392 **10b**), suggesting a significant number of minor subvariants were circulating in the 393 population. Furthermore, using well-barcodes, we showed that the 25% of non-top reads 394 were correctly assigned to the well, and thus do not represent crosswell contamination 395 (Supplementary Fig. 5c, d). Since the quasispecies hypothesis posits that RNA-virus 396 populations contain a high level of genetic variants that form a heterogeneous viral pool within a patient^{18, 19, 20, 21}, we investigated these minor reads in greater detail. The 397 398 abundance of these minor species is reported to be approximately 1%²², which is 399 quantifiable using C19-SPAR-Seq, given the per-patient read depths that were on 400 average 115,685 reads.

401

To search for putative quasispecies (pQS), we took advantage of the barcoded sequencing data we generated for six clinical runs that contained representative samples from WT, Alpha, Delta, and Omicron B.1.1.529 VOCs (**Supplementary Fig. 5c,d**) and selected 1,110 samples to perform minor sequence analysis on barcoded *S-Rbm* sequences as well as non-barcoded *S-Pbs* sequences. The *S-Rbm* barcoding allowed us to account for cross-contamination, which could contribute significant background noise that would confound identification of pQS. We established a run-specific multi-step

409 filtering process to identify pQS within each sample (Fig. 6a). For this, we assessed total 410 S-Rbm read count distribution in each run to identify high quality samples. Across the six 411 clinical runs, we assessed the S-Rbm sequences further by plotting the number of variant 412 sequences as a function of distinct read percentage cutoffs for each run (Fig. 6a). This 413 showed a biphasic distribution with background sequence noise, likely caused by 414 sequencing and PCR errors, increasing exponentially at lower cutoffs. Based on these 415 distributions we assigned run-specific thresholds that minimized background noise, with 416 observed cutoffs ranging between ~0.16-0.31% (Supplementary Fig. 12a). Overall, 417 individual pQS represented less than 5% of the reads for their respective amplicon in both 418 replicates of the barcode analysis for S-Rbm and S-Pbs (replicate 1: mean = 0.376% and 419 standard deviation = 0.676%; replicate 2: mean = 0.311% and standard deviation = 420 0.296%; Supplementary Fig. 13), in accordance with previous reports that guasispecies 421 are found at low frequencies²². We also assessed pQS in non-barcoded S-Pbs reads. 422 Here, the background cutoffs ranged between ~0.127-0.25% (Supplementary Fig. 12b) 423 and 1.89% of the tested samples had sequences passing the cutoffs (Supplementary 424 Fig. 12c).

425

Applying these stringent cutoffs to samples across the four tested VOCs yielded a total of 228 samples with *S-Rbm* pQS (20.5% of samples). WT samples showed the highest proportion of *S-Rbm* pQS (65.98%; **Fig. 6b**), while Alpha, Delta, and Omicron accounted for lower (18.48%, 4.39%, and 11.14%, respectively). Of the *S-Rbm* pQS, we identified 29 distinct species, while pQS frequency and number of distinct species was much less for *S-Pbs* (21 samples and 8 species, respectively; **Supplementary Fig. 12d**). For

432 example, the G496A pQS in S-Rbm was found in 118 different WT samples (Fig. 6c). We 433 identified several samples that possessed multiple pQS in S-Rbm (109) or S-Pbs (1) and 434 9 samples with pQS in both S-Rbm and S-Pbs. Quasispecies analyses suggest that these 435 sequences are not random in nature, but rather cluster around specific mutational profiles. 436 In particular, WT and Alpha were enriched for G496A/C species that were observed in 437 96.89% and 95.24% of total S-Rbm pQS sequences, respectively, but these changes 438 were only in 20% of Delta pQS, where G496R (33.33%) was predominant (Fig. 6b). 439 These highlight G496 as an evolutionary target, and indeed G496S became a defining 440 mutation of the Omicron lineage. Similarly, of the other pQS identified in WT, 5 out of 9 441 variant defining positions in S-Rbm, and one variant defining position in S-Pbs were 442 targeted that would later be mutated in future VOCs (Fig. 6c, Supplementary Fig. 12d, 443 red stars). We also noted that pQS were much more frequent in the S-Rbm compared to 444 S-Pbs (29 unique sequences versus 8), consistent with the key role of the S-Rbm in 445 transmission and immune evasion. Interestingly, analysis of pQS in Omicron BA.1.1.529 446 showed only various combinations of reversion to WT sequences (Fig. 6c), suggesting 447 that the Omicron S-Rbm is highly optimized for transmission (ie ACE2 interaction and 448 immune escape), and that revertants are a favoured evolutionary trajectory. Indeed, 449 R493Q was a WT revertant in Omicron BA 2/3-4/5 and the S-Rbm S496G was a revertant 450 in Omicron BA 2/3-4/5 and XBB.1.5 (Fig. 6c and Supplementary Fig. 14a). Furthermore, 451 although we sampled Omicron the most, only 6.1% of Omicron samples contributed S-452 *Rbm* pQS sequences (**Supplementary Table 7**).

453

455 Mutational variants predict future evolutionary trajectories of SARS-CoV-2

456 To systematically assess whether changes associated with subvariants and pQS in the 457 population might reflect viral sampling of functionally important residues, we developed a 458 mutational compendium for S-Rbm and S-Pbs by combining subvariant and pQS data 459 (Fig 5a, Fig. 6c, Fig. 7a, Supplementary Data 3 and Supplementary Fig. 12d). This 460 showed that S-Rbm was highly susceptible to alterations that often predated VOC 461 emergence, particularly around functional residues (Fig. 7a, left panel). For example, 462 T478 was identified in both subvariants and pQS of WT virus and subsequently emerged 463 in Delta and Omicron VOCs as a T478K mutation. Similarly, E484 and N501, both of 464 which were altered in multiple strains, were identified in WT populations prior to VOC 465 emergence. In Alpha, we noted that changes in F486 and F490 that extinguished by mid-466 2021 (see above, Fig. 5b), re-appeared as subvariants of the parental Omicron strain 467 BA.1.529, and later became fixed as F486P and F490S in XBB.1.5, BA.2.86, and FLip that emerged through to late 2023²³. N481 on the other hand was identified in subvariants 468 469 of later Omicron strains (BA.2, BA.4/5) and emerged in late 2023, as N481K in the 470 BA.2.86 lineage. Interestingly, while the WT virus tended to sample the ACE2 contact 471 residues such as N501 that contributes to ACE2 affinity, subsequent VOCs displayed 472 expansion of variations to include neutralizing Ab contact regions such as F490 and F491 473 (Fig. 7a, upper left panel). Indeed, recent studies show that while alterations in Omicron 474 significantly impact immune recognition, infectivity is variably impacted and typically 475 reduced²³.

476

477 We also analyzed the S-Pbs that showed mutational sampling of residue N679 and P681 478 in WT that was subsequently altered in Alpha (P681H), Delta (P681R), Omicron (N679K) 479 and P681H), and B.2.86 (N679K and P681R; Fig. 7a, right panel). Furthermore, other mutations near the RRxR motif that promote S1/S2 cleavage²⁴ were found as VOC 480 481 subvariants, but did not expand, suggesting they have no major selective advantage for 482 the virus (**Fig. 7a**). Finally, we observed no subvariants or pQS with alterations in R685, 483 which is essential for Furin cleavage. Collectively, these data demonstrate that mapping 484 subvariants and pQS provides predictive and suggest that early viral diversification tends 485 to target viral intrinsic features, while later phases target immune escape.

486

487 Our analysis of subvariants and pQS efficiently identified residues mutationally sampled 488 during SARS-CoV-2 viral evolution, but the specific change that emerged in future 489 variants was rarely identified. Indeed, of 158 S-Rbm and 87 S-Pbs subvariant and pQS 490 changes, only 8 from S-Rbm and 3 from S-Pbs reflected the specific amino acid alteration 491 that would later emerge (Fig. 5a, Fig. 6c, Fig. 7a, Supplementary Data 3 and 492 Supplementary Fig. 12d). Recently, systematic deep mutational scanning (DMS) was 493 performed to measure phenotypes of XBB.1.5 and BA.2 spike proteins, thus providing a 494 map of how all specific mutational changes in Spike impact serum escape, cell entry, and 495 receptor binding ²⁵. We took advantage of this study to determine the functional impact 496 of specific S-Rbm and S-Pbs VOC subvariants and pQS identified by our C19-SPAR-seq 497 pipeline. This showed that most (96%) of observed VOC subvariants and pQS in S-Rbm 498 impacted Spike function, while 79% of S-Pbs alterations targeted residues with DMS 499 scores (Fig. 7b). Many of these changes were measured as advantageous to virus (DMS)

> 0) for human sera escape (36% of *S-Rbm* and 24.3% of *S-Pbs*; Fig. 7b, top panels,
red tiles); Spike-mediated entry (28% of *S-Rbm* and 18.6% of *S-Pbs*; Fig. 7b, middle
panels, red tiles), whereas alterations in S-Rbm targeting ACE2 binding were much less
frequent (13%) compared to 31.4% for *S-Pbs* (Fig. 7b, bottom panels, red tiles). These
studies highlight that the extensive sampling of evolutionary space by SARS-CoV-2 leads
to subvariants and pQS changes that are of relevance for specific viral functions.

506

507 Discussion

508 Population-scale surveillance is crucial to monitor SARS-CoV-2 spreading and its 509 evolution over time. We took advantage of the high-throughput C19-SPAR-seq pipeline 510 to monitor variant spreading and evolution. We screened over 73,510 SARS-CoV-2 511 positive samples from December 2020 to March 2023 (Fig. 1a) and through next-512 generation sequencing were able to capture both the major top-reads as well as the minor 513 read sequences per patient. This data provides a wealth of sequence information across 514 S-Rbm and S-Pbs, two of the most critical regions for viral function and amongst the most 515 mutable within the SARS-CoV-2 genome.

516

517 Our initial C19-SPAR-Seq pipeline was designed to detect the presence or absence of 518 SARS-CoV-2 within patients in a high-throughput and multiplexed manner. Here, we 519 reasoned that our methodology was amenable to survey the mutational landscape and 520 evolution of SARS-CoV-2 at a population level without much change to the existing 521 methodology. While much of the original pipeline was performed by hand on small 522 numbers of samples, population-level surveillance would require a much more robust and

523 high-throughput pipeline. Utilization of robotics to automate the multiplexing, barcoding, PCR and sample pooling significantly speeds up the processing and reduces human 524 and/or clerical errors. Additionally, we have automated the bioinformatics analysis 525 526 pipeline such that the hands-on time from sample acquisition to final data output is less 527 than 2 hours of the 24-hour pipeline (Supplementary Fig. 2). This truly allows for a one-528 day turnaround on patient data which is the gold standard during a global pandemic. While 529 this pipeline is robust for the detection of SARS-CoV-2 variants and mutants as we have 530 highlighted here, we provide it as a highly amenable resource for any potential future viral 531 pandemic.

532

533 To highlight the flexibility of our pipeline, we had to change our PCR strategy for the 534 detection of the S-Rbm around the time of emergence of the Delta VOC, as our initial 535 primers did not capture the T478 residue that defined Delta (Fig. 2b). It was essential that 536 we were quickly and readily able to adapt our C19-SPAR-Seq platform with new primers 537 that generated a longer amplicon allowing us to capture this key residue. Importantly, we 538 implemented this change in only four days and tested the assay performance in four 539 independent clinical runs (Supplementary Fig. 2,3). The speed at which we were able 540 to implement these changes is critical when faced with highly mutable viral pathogens. 541 While we have focused our analysis here on the S-Rbm and S-Pbs amplicons, the design 542 and implementation of primers to other regions of the viral genome could easily be added 543 and multiplexed into our assay pipeline seamlessly.

544

medRxiv preprint doi: https://doi.org/10.1101/2024.07.25.24311007; this version posted July 29, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

545 One concern with large amounts of PCR-based NGS is the potential cross-contamination 546 of patient samples and subsequent calling of false positives and/or negatives. We 547 confirmed that the contamination rate of our pipeline was very low (< 3%) by designing 548 the S-Rbm V2 primers with an additional barcode (Supplementary Fig. 5). The use of 549 these new primers further supports how flexible our assay is to the implementation of new 550 primer pairs. One potential concern about the use of these barcoded primers is that they 551 can become guite costly to use for daily surveillance and monitoring; however, based on 552 the high confidence of correctly mapped reads and well-barcode pairs in our pilot tests 553 (Supplementary Fig. 2,3), we opted to use non-barcoded primers for the majority of the 554 daily surveillance with the idea that they could be used if necessary to detect any potential 555 contamination or to assay pipeline performance in sporadic sequencing runs.

556

557 Within our jurisdiction we were able to report the dynamic of variant spreading that mirrors 558 the worldwide global SARS-CoV-2 evolution and identified the main VOCs as well as 559 major mutations with these VOCs (Fig. 2). Interestingly, we always observed the same 560 repetitive pattern within the population where a VOC would arise as a dominant peak, 561 followed by VOC subvariants that displayed minimal spread, extinguished and were then 562 superseded by the next major incoming VOC (Fig. 2). Importantly, by comparing with 563 DMS we found that most subvariants and pQS led to functionally relevant changes, 564 suggesting that population-level spread is mediated by complex interactions that may not 565 be readily predicted from assays of individual viral functions. Integrating how individual molecular functions combine to enable population-level spread could be an important tool 566 567 for predicting which novel viruses and or their variants are a public health concern.

568

569 Through systematic tracking of variant introductions into the GTA, we noted that spread 570 occurred in waves, raising questions about what mechanisms might underlie these 571 dynamics. NPIs could serve as one mechanism for mitigating disease spread within a 572 population, but we failed to note any specific pattern associated with acceleration waves, 573 suggesting NPIs did not make major contributions to regulating the spread of SARS-CoV-574 2 within our jurisdiction. Similar conclusions with respect to the impact of school closings 575 have been reached^{26, 27}, while analysis of viral spread in New York City suggests local geographic constraints might also contribute to this pattern¹⁴. Furthermore, human social 576 577 networks display substructure with peak degrees of interaction of approximately 150²⁸. 578 This substructure, possibly modified by geographic considerations, vaccination, and prior 579 exposure, may thus collectively create social layers that act to blunt viral spread. 580 Importantly, since current mathematical models, such as the SIR model²⁹, assume 581 homogeneity in social networks, they may not be accurate models of viral expansion 582 within the population. In the future it would be of interest to investigate how each of these 583 factors might affect wave dynamics and potential impact of pathogenic viruses in large 584 populations.

585

586 Analysis of the major VOC mutations revealed that the initial WT Wuhan strain and 587 subsequent VOCs often gave rise to subvariants with acquired mutations in residues that 588 often became defining features of later VOCs (**Fig. 3,4, and 7**). Furthermore, 589 approximately 25% of our sequencing reads for any given sample did not belong to the 590 predominant sequence and do not constitute contamination (**Supplementary Fig. 5**). For

591 RNA viruses, guasispecies represent the low abundance sequences and heterogeneity 592 found within a patient sample that may lay the foundation for the emergence and evolution 593 of new mutants^{18, 19, 20, 21, 22}. We therefore developed a stringent filtering strategy that 594 employed well bar-coding to identify pQS from these high-quality samples and found 595 repeated sequence patterns associated with specific VOCs, consistent with QS theory. 596 This identified 29 unique pQS in S-Rbm and 8 in S-Pbs, with certain targeted residues 597 that would eventually be mutated in future VOCs. By combining subvariant and pQS 598 monitoring, saily real-time surveillance could thus seed a predictive diagnostic platform 599 that learns the future evolutionary trajectory of highly infectious and/or virulent viruses. 600 This could be an important arm of a One Health strategy that seeks to profile mutational 601 dynamics of high risk viruses with zoonotic potential, such as highly pathogenic avian 602 influenza virus.

603

604 In summary, we have developed and optimized our previously reported C19-SPAR-Seq 605 pipeline and deployed it to profile 73,510 SARS-CoV-2-positive patients collected from 606 December 2020 to March 2023 within our jurisdiction. We utilized this platform to identify 607 VOCs, characterize VOC expansion patterns, and prospectively identify mutations 608 characteristic of future evolutionary trajectories. Our development of a systematic, high 609 intensity, relatively low-cost sequencing platform could serve as a blueprint for NGS-610 based surveillance of other highly mutable pathogens at risk of evolving large-scale 611 transmission characteristics.

612 Methods

613 Samples collection, Total RNA extraction, and control samples

614 Positive patient samples were obtained from the Department of Microbiology at Mount 615 Sinai Hospital under MSH REB Study #21-0099-E - Mapping the Emergence and 616 Functional Impact of Novel SARS-CoV-2 Variants. RNA from positive samples was 617 extracted with MGIEasy Nucleic Acid Extraction Kit. We designed and generated the four 618 S gene RNAs to use as an internal control for each C19-SPAR-Seg run or as a matrix for 619 well-BC-S-Rbm-V2 primers. pcDNA3.1 containing the S gene was purchased from 620 Synbio-Technologies. Site-directed mutagenesis was performed to introduce silent mutations into the amplicon region of each gene using the indicated primers and PCR 621 622 with KOD followed by DpnI (NEB) digestion of the wild-type template DNA (see 623 **Supplementary Data 4).** Successful mutagenesis was confirmed by Sanger sequencing. 624 Single-stranded RNA of each mutant was subsequently produced by *in vitro* translation 625 using the MEGAscript T7 kit (Invitrogen). The four S mutants were used sequentially in 626 the C19-SPARseq as technical control.

627

628 C19-SPAR-Seq primer design and optimization

C19-Spar-Seq used optimized multiplex PCR primers for SARS-CoV-2 (S, *N*, and *RdRP*)
and human *ACTB* genes with amplicon size > 100 bases (Supplementary Table 1). In
this study we used *S-Rbm* V2 primers to generate a larger *Rbm* amplicon (Supplementary
Table 1) and well barcoded S-*Rbm*-V2 primers to deconvolute inter- and intrawell
contamination as well as determine true minor sequencing mutants (Supplementary
Table 4)

635 Master Mix plates preparation

Reverse Transcript, Multiplex PCR, and Barcode PCR master mix plates (without enzyme
and patient samples) were prepared *ex tempo* in 384 well plates in the pre-PCR station.
The barcode primer plates were prepared by STARPlus in the pre-PCR station too.
Enzymes (Reverse transcriptase and Polymerase) were dispensed by Echo 555, and
RNA, cDNA of patient samples, and the barcode primers were added by the Biomek NxP *ex tempo*.

642

643 Reverse Transcription (RT)

Total RNA was reverse transcribed using SuperScript[™] IV Reverse Transcriptase 644 645 (Invitrogen) in 5X First-Strand Buffer containing DTT, a custom mix of Oligo-dT (Sigma), 646 and Hexamer random primers (Sigma), dNTPs (Genedirex). We followed the 647 manufacturer's protocol. Each reaction included: 0.25 µL Oligo-dT, 0.25 µL hexamers, 648 0.5 µL dNTP (2.5 mM each dATP, dGTP, dCTP, and dTTP), 2 µl 5X First-Strand Buffer, 649 0.5 µl 0.1 M DTT, quantum satis (qs) 5.5 µL RNase/DNase free water. Then 0.5 µl of 650 SuperScript[™] IV RT (200 units/µI) using Echo 555 robotic and 4 µL purified Total RNA 651 was added by Biomek NxP. Samples were incubated at 25°C for 10', 50°C for 10', 80°C 652 for 10', and then stored at 4°C. cDNA was diluted in RNase/DNase-free water at $\frac{1}{5}$ by 653 Biomek NxP.

654

655 Multiplexing PCR

656 The multiplex PCR reaction was carried out using Phusion polymerase (ThermoFisher).

657 The manufacturer's recommended protocol was followed with the following primer

658 concentrations: Spoly at 0.05µM, SRbm at 0.05µM, RdRP at 0.05µM, and ActB at 659 0.025µM for C19-SPAR-Seq V1 and Spoly at 0.038µM, SRbm-V2 at 0.1µM, RdRP at 660 0.017µM, and ActB at 0.025µM for C19-SPAR-Seg V1.2. For each reaction: 2 µL 5X 661 Phusion buffer, 0.2 µL dNTP (2.5 mM each dATP, dGTP, dCTP, and dTTP), primers, *qs* 662 5.9 μ L RNase/DNase free water, then 0.1 μ L Phusion Hot start polymerase and 4 μ L of 663 diluted cDNA were added by Echo 555 and Biomek NxP respectively. The thermal cycling 664 conditions were as follows: one cycle at 98°C for 2', and 30 cycles of 98°C for 15", 60°C 665 for 15", 72°C for 20", and a final extension step at 72°C for 5' and then stored at 4°C. 666 Primer sequences are listed in **Supplementary Table 1**.

667

668 Barcoding PCR

669 For multiplex barcode sequencing, dual-index barcodes were used⁸. The second PCR reaction on multiplex PCR was performed using the Phusion polymerase (ThermoFisher). 670 671 For each reaction: 2 µL 5X Phusion buffer, 0.2 µL dNTP (2.5 mM each dATP, dGTP, 672 dCTP, and dTTP), 2 µL Barcoding primers F+R (pre-mix), qs 5.9µL RNase/DNase free 673 water, then 0.1 μ L Phusion polymerase, 4 μ L of multiplex PCR reaction were added by 674 Echo 555 and Biomek NxP respectively. The thermal cycling conditions were as follows: one cycle at 98°C for 30", and 15 cycles of 98°C for 10", 65°C for 30", 72°C for 30", and 675 676 a final extension step at 72°C for 5' and stored at 4°C.

677

678 Library preparation and Sequencing

679 Libraries were pooled by Biomex Fx. Each sample was pooled (7uL/sample) and library
680 PCR products were purified twice with SPRIselect beads ratio 1:1 (beads/library)

681 (A66514, Beckman Coulter). All libraries were sequenced with MiSeg or NextSeg 300 or

682 MiniSeq (Illumina) using 100bp single-end sequencing. well-BC libraries were sequenced

using Paired-end with Read 1: 144 cycles and Read 2: 8 cycles.

684

685 Whole Genome Sequencing

686 Sequencing libraries were prepared from extracted patient RNAs using Qiagen QIAseq 687 SARS-CoV-2 Primer Panel (Cat# 333896) according to the manufacturer's instructions. 688 Library fragment size was then checked using an Agilent Fragment Analyzer and 689 quantified with qPCR using Collibri™ Library Quantification Kit (ThermoFisher, 690 Cat#A38524500) on a BioRad CFX96 Touch Real-Time PCR Detection System. Quality-691 checked libraries were loaded onto an Illumina NextSeq 500 running with PE 150 cycles. 692 Real-time base call (.bcl) files were converted to FASTQ files using Illumina bcl2fastq2 693 conversion software v2.17 (on CentOS 6.0 data storage and computation Linux servers). 694 The genome mapping and variant calling were performed by CLC Genomics Workbench 695 V21.0.1 with QIAseq SARS-CoV2 workflow V1.0. The resulting consensus sequences 696 were then uploaded to Pangolin for lineage assignment.

697

698 Cloning and Recombinant Expression of Variants RBM

SARS-CoV2 variant amplicons were obtained by PCR from cDNA generated from reverse
transcribed patient samples collected and sequence verified during the recent SARSCoV2 pandemic. The wild-type (Wuhan variant), Alpha, Beta, Delta, Omicron, and novel
(F490L) variants RBM residues 319 - 596 fused with a human signal sequence at the Nterminal were cloned into a pFastBacl vector modified to contain bacterial Biotin ligase

(BirA) recognition motif and poly-Histidine tag to the C-terminus. Constructs were
expressed as described³⁰. Media was dialyzed against a buffer containing 200 mM NaCl,
40 mM Tris HCl pH 7.5, and 10 mM Imidazole overnight. Dialyzed media was incubated
in Nickel NTA beads, washed in a Buffer containing 10mM Imidazole, and RBM-His was
eluted with 150mM Imidazole.

709

710 **RBM Biotinylation**

One mg of variants RBM was biotinylated overnight at room temperature in buffer containing 15mL of 1 mg/mL *E. coli* BirA Biotin Ligase, 100 ml of buffer mix B (25 ml 500mM ATP, 25 mL 500mM MgOAc, 62.5Ml D-Biotin 1mM in 0.5M Bicine made up with 12.5 mL ddH₂O) and purified on 24 mL size exclusion Superdex-200 Column. Biotinylated RBM protein was concentrated, estimated, and stored away at -80°C until used.

716

717 Determination of SARS-CoV-2 RBM-hACE2 Affinity

718 The affinity between hACE2 and the SARS-CoV-2 S- RBM were determined using 719 streptavidin (SA) biosensors and the Octet RED96 system (ForteBio Inc., Menlo Park, 720 CA, USA). First, the recombinant RBMs were biotinylated, purified on a size-exclusion 721 column (Superdex S75), and immobilized on the SA biosensors at 10 µg/mL in a working 722 buffer containing 25 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.05% Tween-20, and 0.1% 723 BSA. The biosensors were hydrated in the working buffer for 30 minutes at room 724 temperature prior to RBM loading. The hACE2 was diluted in the same working buffer in 725 a two-fold serial dilution series from 970 nM to 15.2 nM (7 different concentrations). The 726 interactions were measured by incubating the loaded sensors in parallel with the seven

concentrations of hACE2 and one with only a working buffer as control. The real-time binding response ($\Delta\lambda$ in nanometers, nm) at each concentration was corrected by subtracting the background signal measured in the control sample. The kinetic parameters and affinities were estimated based on a one-to-one binding model with a global fit of the data, using the Octet data analysis software (version 7.1, ForteBio Inc., Menlo Park, CA, USA).

733

734 Data Processing

735 The fast files were demultiplexed with bcl2fast and aligned with bowtie (v 0.12.7 with 736 settings --best -v 3 -k 1 -m 1 -S) and counts were guantified with HTSeq-count (v0.13.5 737 with settings -f sam -t CDS). Custom python scripts (python v3.9) were developed to 738 identify, track, and quantify key mutations (Supplementary Fig2) in the amplicons within 739 samples and to aggregate the data. In early analysis versions, custom R scripts (R v4.1.1 740 with packages dplyr and openxlsx) were used to apply a quality control filter based on 741 H2O control total viral amplicon counts. In intermediate versions, the minimum read cutoff 742 was calculated as [(median of the control sample S-Rbm amplicon counts) + (2*(median 743 absolute deviation of control sample S-Rbm amplicon counts))] or a minimum value of 10, 744 whichever is higher. An S-Rbm coverage filter to determine confidence in the top read 745 was specified as a 15 percentage point minimum difference between the proportion of 746 WT reads to the top read variants within a sample (for samples where the top read variant 747 was not WT). In final versions of the processing pipeline, the QC functions were added to 748 the python script, the median S-Rbm-v2 viral read count cutoff was expanded to include 749 all H2O, HEK, and NoRT controls, and the S-Rbm filters were applied to the S-Rbm-v2

750	amplicon instead. Additionally, the final pipeline version is wrapped into a shell script
751	which executes data processing and QC checks in one command.

752

753 Well-Barcoding Methods

To quantify well-to-well contamination we devised a new set of S-*Rbm* PCR barcodes for the rows (R1) and columns (R2) on a 384-well plate. With minor modifications to our existing V2 analysis pipeline, we added R2 processing to assess pairs of reads. Additional code checks for read pairs and then tracks the percentage of each valid row and column PCR barcode pair. We tested 7 plates and found that for non-control samples across all plates, sequences with the correct unique PCR barcode pair assigned to the well made up, on average, 97% of the *S-Rbm* reads per well.

761

762 Rate of Change of Variant Analysis

763 To calculate VOC case slopes and quantify the rate of change of slopes, the data 764 aggregated for selected VOCs is subsetted per collection day, then quantified against the 765 daily case total across all VOCs to calculate the daily proportion of each VOC. The time in days since the first case of the VOC is calculated with the lubridate package³¹ and 766 767 linear models are fitted to the data in sliding windows of 5 days with the Im() function to 768 obtain a slope. Missing data is imputed by taking the average of the previous day and the 769 next day's values. Finally, the slopes are visualized as a heatmap with the x axis 770 representing the first day of the 5-day window to assess the dynamics of the VOC over 771 time.

773 Quasispecies Detection

774 Using the data with S-Rbm PCR well-barcodes, we analyzed viral quasispecies in the 775 samples, split into groups by run ID and variant call. Samples failing QC in the normal 776 pipeline, or without a confident variant call, were excluded. Processing is done per run-777 variant group with a set of custom python and shell scripts (https://github.com/wrana-778 lab/SPARSEQ_QUASISPECIES). For each sample, the forward and reverse barcodes 779 are checked to verify that they match the sample's well. Reads surpassing a minimum 780 length are trimmed to remove barcodes and primers and sorted into groups of unique 781 sequences. The groups are quantified as percentages of the total set of sequences per 782 amplicon and per sample, and the most prevalent sequence is dropped. Sequences 783 passing a minimum count threshold are aggregated for further analysis. A set of seven 784 minimum thresholds (0.01%, 0.02%, 0.05%, 0.1%, 0.2%, 0.5%, 1%) are used to assess 785 background levels of sequences per run-variant group. The resulting counts of pQS from 786 the three least stringent cutoffs are used to fit a linear model to calculate the x-intercept 787 for the run-variant group, which is used for a final round of processing as a customized 788 cutoff. Finally, each set of resulting sequences is compared to the corresponding 789 repeated group, and sequences found in the same sample in both copies of the samples 790 are aligned and presented as finalized guasispecies sequences. Any sample where over 791 5% of the reads are identified as pQS is filtered out. This process was repeated for S-792 Pbs sequences; however, these sequences were not barcoded, so the barcode-matching 793 portion of the pipeline was not applied.

794

795

796 Code Availability

- All of the code required to reproduce these findings and to perform the C19-SPAR-Seq
- analysis pipeline is available at <u>https://github.com/wrana-lab/SPARseq</u>.
- 799

800 Data Availability

- 801 Data that support the findings of this study have been deposited in the NCBI Gene
- 802 Expression Omnibus (GEO) under the SuperSeries GSE231416
- 803 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE231416) which contains the
- following subsets: the main dataset including the sample data table is under GSE224951;
- the well-barcoded dataset is under GSE231415; and the well-barcoded repeat dataset is
- 806 under GSE246819.

808 References

- 809 1. Zhou P, *et al.* A pneumonia outbreak associated with a new coronavirus of
 810 probable bat origin. *Nature* 579, 270-273 (2020).
- 811 2. WHO. Coronavirus disease 2019 (COVID-19): dashboard. World Health
- 812 Organization https:// covid19.who.int/.
- 813 3. consortiumcontact@cogconsortium.uk C-GU. An integrated national scale SARS-
- 814 CoV-2 genomic surveillance network. *Lancet Microbe* **1**, e99-e100 (2020).
- 815 4. Rambaut A, et al. Preliminary genomic characterisation of an emergent SARS-
- 816 CoV-2 lineage in the UK defined by a novel set of spike mutations. Genom Epidemiol,
- 817 (2020).
- 5. Tegally H, et al. Detection of a SARS-CoV-2 variant of concern in South Africa.
- 819 Nature **592**, 438-443 (2021).
- 820 6. Faria NR, *et al.* Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in
 821 Manaus, Brazil. *Science* **372**, 815-821 (2021).
- 822 7. Starr TN, *et al.* Deep Mutational Scanning of SARS-CoV-2 Receptor Binding
 823 Domain Reveals Constraints on Folding and ACE2 Binding. *Cell* 182, 1295-1310 e1220
 824 (2020).
- 825 8. Greaney AJ, *et al.* Complete Mapping of Mutations to the SARS-CoV-2 Spike
 826 Receptor-Binding Domain that Escape Antibody Recognition. *Cell Host Microbe* 29, 44827 57 e49 (2021).
- 828 9. Aynaud M-M, *et al.* A multiplexed, next generation sequencing platform for high829 throughput detection of SARS-CoV-2. *Nature Communications* **12**, 1405 (2021).
- 830

- 831 10. Walker AS, *et al.* Tracking the Emergence of SARS-CoV-2 Alpha Variant in the
 832 United Kingdom. *N Engl J Med* 385, 2582-2585 (2021).
- 833 11. Konings F, et al. SARS-CoV-2 Variants of Interest and Concern naming scheme
- conducive for global discourse. *Nat Microbiol* **6**, 821-823 (2021).
- 835 12. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin
 836 of SARS-CoV-2. *Nat Med* 26, 450-452 (2020).
- 837 13. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure,
 838 Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* 181, 281-292
 839 e286 (2020).
- 840 14. Dellicour S, et al. Variant-specific introduction and dispersal dynamics of SARS-
- 841 CoV-2 in New York City from Alpha to Omicron. *PLoS Pathog* **19**, e1011348 (2023).
- 842 15. Smallman-Raynor MR, Cliff AD, Consortium C-GU. Spatial growth rate of
 843 emerging SARS-CoV-2 lineages in England, September 2020-December 2021.
 844 *Epidemiol Infect* **150**, e145 (2022).
- 845 16. Ontario. Eligibility for PCR Testing and Case and Contact Management Guidance846 in Ontario. In: *News ontario*).
- 17. Domingo E, Perales C. Viral quasispecies. *PLoS Genet* **15**, e1008271 (2019).
- 848 18. Andino R, Domingo E. Viral quasispecies. *Virology* **479-480**, 46-51 (2015).
- 849 19. Nowak MA. What is a quasispecies? *Trends Ecol Evol* **7**, 118-121 (1992).
- 850 20. Xu D, Zhang Z, Wang FS. SARS-associated coronavirus quasispecies in individual
- 851 patients. *N Engl J Med* **350**, 1366-1367 (2004).
- 852 21. Al Khatib HA, et al. Within-Host Diversity of SARS-CoV-2 in COVID-19 Patients
- 853 With Variable Disease Severities. *Front Cell Infect Microbiol* **10**, 575613 (2020).

- B54 22. Jary A, et al. Evolution of viral quasispecies during SARS-CoV-2 infection. *Clin Microbiol Infect* 26, 1560 e1561-1560 e1564 (2020).
- 856 23. Qu P, et al. Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2
 857 Omicron BA.2.86 and FLip Variants. *bioRxiv*, (2023).
- 858 24. Ord M, Faustova I, Loog M. The sequence at Spike S1/S2 site enables cleavage
- by furin and phospho-regulation in SARS-CoV2 but not in SARS-CoV1 or MERS-CoV.
- 860 *Sci Rep* **10**, 16944 (2020).
- 861 25. Dadonaite B, et al. Spike deep mutational scanning helps predict success of
 862 SARS-CoV-2 clades. *Nature* 631, 617-626 (2024).
- 863 26. Neil-Sztramko SE, *et al.* What is the specific role of schools and daycares in
 864 COVID-19 transmission? A final report from a living rapid review. *Lancet Child Adolesc*865 *Health* 8, 290-300 (2024).
- Tan W. School closures were over-weighted against the mitigation of COVID-19
 transmission: A literature review on the impact of school closures in the United States. *Medicine (Baltimore)* 100, e26709 (2021).
- 869 28. West BJ, *et al.* Relating size and functionality in human social networks through
 870 complexity. *Proc Natl Acad Sci U S A* **117**, 18355-18358 (2020).
- 871 29. Nguyen TK, Hoang NH, Currie G, Vu HL. Enhancing Covid-19 virus spread
 872 modeling using an activity travel model. *Transp Res Part A Policy Pract* 161, 186-199
 873 (2022).
- 874

875 30. Shang J, *et al.* Structural basis of receptor recognition by SARS-CoV-2. *Nature*876 581, 221-224 (2020).

- 877 31. Grolemund G, Wickham H. Dates and Times Made Easy with lubridate. *Journal of*878 *Statistical Software* 40, 1 25 (2011).
- 879
- 880 32. Gavor E, Choong YK, Er SY, Sivaraman H, Sivaraman J. Structural Basis of
- 881 SARS-CoV-2 and SARS-CoV Antibody Interactions. *Trends Immunol* **41**, 1006-1022
- 882 (2020).
- 883 33. Verkhivker G. Structural and Computational Studies of the SARS-CoV-2 Spike
- 884 Protein Binding Mechanisms with Nanobodies: From Structure and Dynamics to Avidity-
- 885 Driven Nanobody Engineering. Int J Mol Sci 23, (2022).
- 886 34. Naidoo DB, Chuturgoon AA. The Potential of Nanobodies for COVID-19
 887 Diagnostics and Therapeutics. *Mol Diagn Ther* 27, 193-226 (2023).
- 888
- 889
- 890

891 Figure legends

892 Fig. 1 Integration of C19-SPAR-Seq to detect SARS-CoV-2 Variants of Concern. a. 893 Schematic representation of the preclinical testing of patient samples for SARS-CoV-2 894 (Step 1) and the C19-SPAR-Seg multiplex sequencing pipeline (Step 2) to identify 895 variants of concern. b. Analysis of SARS-CoV-2-positive patient samples by C19-SPAR-896 Seq V1. A pilot cohort (n = 1,198) was analyzed by C19-SPAR-Seq and the Z-score of 897 log₁₀ (read counts+1) for each of the indicated amplicons is presented in a heatmap. 898 Samples are ordered from lowest to highest read counts for S-Rbm, with negative control 899 samples on the right (n = 20). **c**. Representative alignment of top read counts for S-Rbm. 900 Seven representative cases are shown aligned to the S-Rbm reference sequence, 901 nucleotide substitutions are shown in red within the sequence and amino acid changes 902 are highlighted in a red box. The Variant of Concern (VOC) that each sample contains is 903 shown on the right of the sequence. d. Quantification of all major mutations observed in 904 the pilot cohort. The frequency of each observed mutation is indicated. e. Number of C19-905 SPAR-Seq runs per week (Y-axis) from December 2020 to March 2023 (X-axis). Red 906 bars are runs with the multiplex primer V1 and blue bars are runs with the multiplex V2 907 primers of the C19-SPAR-seq pipeline. f. Description of the number of samples run 908 through the C19-SPAR-Seq (red).

909

910

912 Fig. 2 Results of an Improved C19-SPAR-Seq V2 pipeline. Line graph of the total 913 number of cases for each canonical VOC from December 2020 to March 2023 (upper 914 panel). Percentage of the weekly cases of the variants, the peaks and cross-over are 915 indicated with dot and dashed lines respectively (lower panel).

916

917 Fig. 3 Variant dynamic and Non-Pharmaceutical Interventions (NPIs). a. Schematic 918 of the procedure to track the dynamic spread of the virus (see Methods) showing the 919 proportion of Alpha, Delta and Omicron cases with representation of linear models along 920 sliding 5 days windows (red line) (upper panel). Slopes from each linear model (lower 921 panel). b. Dynamic spread using slopes of WT, Alpha, Delta and Omicron B1.1.529. NPIs 922 are plotted (red lines indicate closures or restrictions and green lines indicate openings;

923 see Supplementary Table 6)

924

925 Fig. 4 Population-level surveillance of variant dynamics by C19-SPAR-Seq. a. 926 Quantitation of all major mutations observed in the pilot cohort. The frequency of each 927 observed mutation is plotted and color-coded based on their location in the SARS-CoV-928 2 genome **b.** Phylogenetic tree of the WT strain and the early variants. **c.** Binary heat map 929 of each canonical VOC and non-canonical VOC ordered by date of first detection. Within 930 each coloured box is each mutant that shares a common VOC sequence trace. d. For 931 each variant, the percentage of canonical VOC is shown with a solid line, and the 932 percentage of mutant VOC is represented with a dash-line.

933

934 Fig. 5 Major VOC subvariants within the S-Rbm and S-Pbs sequences. a. Percentage 935 of top reads with a mutation detected in a given amino acid in S-Rbm and S-Pbs. The 936 percentage of a point mutation at each amino acid position is shown. Canonical VOCs 937 mutations are indicated in grey. The binding site of S-Rbm with hACE2 (black tiles) and 938 9 neutralizing antibodies are shown (white-purple scale, with darker purple indicating 939 contact with more antibodies)^{32, 33, 34}, as well as the S-Pbs cleavage site (S1 subunit 940 indicated in purple, S2 subunit indicated in yellow) **b.** Heatmap of case counts of the top 941 14 key subvariants and the circulation time (time from the 1st-last case) are plotted with 942 functional subvariants shown in red and non-functional subvariants shown in light blue.

943

Fig. 6 Detection of putative quasispecies by C19-SPAR-Seq. a. Schematic of pQS
detection. b. Percentage of putative quasispecies detected in *S-Rbm* and *S-Pbs*sequences on WT, Alpha, Delta, and Omicron B.1.1.529 samples. c. *S-Rbm* and *S-Pbs*putative quasispecies sequences.

948

Fig. 7 Functional Impact of VOC subvariants and putative quasispecies. a. Summary
of all mutations and/or putative quasispecies found in *S-Rbm* and *S-Pbs. S-Rbm* and *S- Pbs* reference sequences are indicated with VOC-associated changes highlighted in red.
At top left, the binding site of *S-Rbm* with hACE2 (black tiles) and 9 neutralizing antibodies
are shown (white-purple scale, with darker purple indicating contact with more
antibodies)^{32, 33, 34}, as well as the *S-Pbs* cleavage site at top right (S1 subunit indicated in
purple, S2 subunit indicated in yellow). Changes identified in pQS (purple), subvariants

956 (blue), or both (pink) identified in the indicated VOC are shown. Each variant defining 957 mutations are highlighted in blue for each variant **b.** Functional impact of VOC subvariants 958 and pQS alterations. Alterations identified in systematic screening were compared with functional profiling of Spike deep mutational scanning²⁵. Upper panel shows scores 959 960 obtained for human sera escape, middle panel shows scores from Spike-mediated entry, 961 and lower panel shows scores for ACE2 binding (S-Rbm on left, S-Pbs on right). For each 962 heatmap, scales for deep mutational scanning scores are shown, with scores above 0 963 indicating an advantage for viral expansion and highlighted with red outlines. Negative 964 values are blue, indicating no advantage, and are not highlighted. Grey boxes indicate 965 NA values.

966

967 Acknowledgments

968 The authors are grateful to all the people who reported to COVID-19 test centers in 969 Toronto and the GTA.

970 This work is supported by Canadian Institutes of Health Research (Grant #177705) 971 awarded by L.P. and J.L.W. The authors wish to thank the Network Biology Collaborative 972 Centre Robotics Facility (RRID: SCR_025391) at the Lunenfeld-Tanenbaum Research 973 Institute for the automation of the C19-SPAR-Seq platform. The facility is supported by 974 the Canada Foundation for Innovation and the Ontario Government. The facility is 975 supported by the Canada Foundation for Innovation and the Ontario Government. Work 976 in the Pelletier lab was funded by CIHR Foundation (FDN # 167279) and Krembil 977 Foundation. L.P. is a Tier 1 Canada Research Chair in Centrosome Biogenesis and

978 Function. K.N.A. was supported by Medicine by Design Postdoctoral and H.L. Holmes979 Postdoctoral Fellowships.

980

981 Author contributions

J.L.W., K.N.A., and M.M.A. designed the study. M.M.A., R.P., M.J., P.M.V., N.D., L.Z.,

983 A.A-F., F.Y., and A.A. performed C19-SPAR-Seq experiments. L.C., K.N.A., S.P, K-R.Z,

A.O., and S.B performed NGS analysis and established the C19-SPAR-Seq interpretation

985 pipeline. L.C., K-R.Z, A.O., and S.B updated and maintained the code. L.C. aggregated

and managed the dataset and performed data analysis. M.M.A. and K.N.A. assisted with

987 the rest of the analysis. K.C. performed sequencing. M.M.A. and M.J. set up the pipeline

988 automation. A.A.O, M.J, and K.C. performed biochemistry experiments on the variant

affinity assay under the supervision of J.R. and J.L.W.. T.M. provided access to patient

samples, collection of diagnostics information, and assembly of the cohorts. P.Y., J.S,

991 J.B., I.L., and B.G.W. coordinated the access to patient samples and generated WGS

993 manuscript was written by M.M.A., L.C., K.N.A., L.P., and J.L.W. with input from T.M.and

data. All experiments were carried out under the supervision of L.P and J.L.W. The

994 J.R.

995

992

996 Ethical declarations

997 **Competing Interests statement**

998 The authors declare no competing interests.









(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



Fig. 2

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license





Slope 0.10 0.05 0.00 0.05 0.10

Fig. 3



(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .







а

Fig. 6

